Resistance to gefitinib and cross‐resistance to irreversible EGFR‐TKIs mediated by disruption of the Keap1‐Nrf2 pathway in human lung cancer cells-Reference-Cited by-同舟云学术

Resistance to gefitinib and cross‐resistance to irreversible EGFR‐TKIs mediated by disruption of the Keap1‐Nrf2 pathway in human lung cancer cells

Published:2018-05-29 Issue:11 Volume:32 Page:5862-5873
ISSN:0892-6638
Container-title:The FASEB Journal
language:en
Short-container-title:FASEB j.

Author:

Park Seong-Hee¹²,Kim Jae Hwan¹²,Ko Eunsun¹²,Kim Jeong-Yub¹³,Park Myung-Jin³,Kim Min Jung⁴,Seo Hyemin⁴,Li Shibo⁵,Lee Ji-Yun¹

Affiliation:

1. Department of Pathology, College of MedicineKorea UniversitySeoulSouth Korea

2. Department of Biomedical Science, College of MedicineKorea UniversitySeoulSouth Korea

3. Division of Radiation Cancer Research, Research Center for Radio-SenescenceKorea Institute of Radiological and Medical Sciences (KIRAMS)SeoulSouth Korea

4. Department of Biological SciencesSookmyung Women's UniversitySeoulSouth Korea

5. Department of Pediatrics, College of MedicineUniversity of Oklahoma Health Sciences Center (OUHSC)Oklahoma CityOklahomaUSA

Funder

National Research Foundation of Korea

Publisher

Wiley

Subject

Genetics,Molecular Biology,Biochemistry,Biotechnology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1096/fj.201800011R

Reference45 articles.

1. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

2. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

3. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

4. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

5. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. N6‐methyladenosine‐mediated LINC01087 promotes lung adenocarcinoma progression by regulating miR‐514a‐3p to upregulate centrosome protein 55;The Kaohsiung Journal of Medical Sciences;2024-07-18

2. Inhibition of NRF2 signaling overcomes acquired resistance to arsenic trioxide in FLT3-mutated Acute Myeloid Leukemia;Annals of Hematology;2024-04-17

3. Predicting drug response through tumor deconvolution by cancer cell lines;Patterns;2024-04

4. Nutlin-3a induces KRAS mutant/p53 wild type lung cancer specific methuosis-like cell death that is dependent on GFPT2;Journal of Experimental & Clinical Cancer Research;2023-12-14

5. A NRF2 inhibitor selectively sensitizes KEAP1 mutant tumor cells to cisplatin and gefitinib by restoring NRF2-inhibitory function of KEAP1 mutants;Cell Reports;2023-09